#Zanidatamab

Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act

Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.